Phenobarbital does not promote hepatic tumorigenesis in a twenty-six- week bioassay in p53 heterozygous mice

Toxicologic Pathology

Volumn 26, Issue 4, 1998, Pages 492-500

  Sagartz, John E ^a   Curtiss, Sandra W ^a   Bunch, Roderick T ^a   Davila, Julio C ^a   Morris, Dale L ^a   Alden, Carl L ^a  

^a PFIZER INC   (United States)

Author keywords

Bioassay; Carcinogenesis; Liver; Neoplasia; P Cresidine; Urinary bladder

Indexed keywords

PHENOBARBITAL; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; BLADDER TUMOR; BODY WEIGHT; CARCINOGEN TESTING; CARCINOGENESIS; CONTROLLED STUDY; GENOTOXICITY; GENOTYPE; HETEROZYGOTE; LIVER WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

ANIMALIA; RODENTIA;

EID: 0031872777     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339802600405     Document Type: Article

References (31)

1. 1 mice. Vet. Pathol. 28: 381-388.
2. Alden CL, Smith PF, Piper CE, and Brej L (1996). A critical appraisal of the value of the mouse cancer bioassay in safety assessment. Toxicol. Pathol. 24: 722-725.
3. Baylin SB, Herman JG, Graff JR, Vertino PM, and Issa JP (1998). Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv. Cancer Res. 72: 141-196.
4. Carmichael NG, Enzmann H, Pate I, and Waechter F (1997). The significance of mouse liver tumor formation for carcinogenic risk assessment and conclusions from a survey of ten years of testing by the agrochemical industry. Environ. Health Perspect. 105: 1196-1203.
5. Caron de Fromentel C and Soussi T (1992). p53 tumor suppressor gene: A model for investigating human mutagenesis. Genes Chromosomes Cancer 4: 1-15.
6. Conney AH (1967). Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. 19: 317-366.
7. Diwan BA, Rice JM, Ohshima M, and Ward JM (1986). Interstrain differences in susceptibility to liver carcinogenesis initiated by N-nitrosodiethylamine and its promotion by phenobarbital in C57BL/ 6NCr, C3H/HeNCrMTV-and DBA/2NCr mice. Carcinogenesis 7: 215-220.
8. Diwan BA, Rice JM, Ohshima M, Ward JM, and Dove LF (1985). Comparative tumor-promoting activities of phenobarbital, amobarbital, barbital sodium, and barbituric acid on livers and other organs of male F344/NCr rats following initiation with N-nitrosodiethylamine. J. Natl. Cancer Inst. 74: 509-516.
9. Eastin WC, Haseman JK, Mahler JF, and Bucher JR (1998). The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens. Toxicol. Pathol. 26: 461-473 (this issue).
10. Ginsberg D, Mechta F, Yaniv M, and Oren M (1991). Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88: 9979-9983.
11. Goodrrow TL, Storer RD, Leander KR, Prahalada SR, van Zwieten MJ, and Bradley MO (1992). Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors. Mol. Carcinog. 5: 9-15.
12. Harvey M, McArthur MJ, Montgomery CA Jr, Bradley A, and Donehower LA (1993). Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 7: 938-943.
13. Harvey M, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A, and Donehower LA (1993). Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet. 5: 225-229.
14. Hollstein M, Sidransky D, Vogelstein B, and Harris CC (1991). p53 mutations in human cancers. Science 253: 49-53.
15. International Conference on Harmonization (1997). Tripartite Guideline, Step 4.
16. Kress S, Konig J, Schweizer J, Lohrke H, Bauer-Hofmann R, and Schwarz M (1992). p53 mutations are absent from carcinogen-induced mouse liver tumors but occur in cell lines established from these tumors. Mol. Carcinog. 6: 148-158.
17. Masuda H, Miller C, Koeffler HP, Battifora H, and Cline MJ (1987). Rearrangement of the p53 gene in human osteogenic sarcomas Proc. Natl. Acad. Scei. USA 84: 7716-7719.
18. McClain RM (1995). Phenobarbital mouse liver tumors: Implications of hepatic tumor promotion for cancer risk assessment. In: Growth Factors and Tumor Promotion: Implications for Risk Assessment. Wiley-Liss, New York, pp. 325-336.
19. McClain RM, Posch RC, Bosakowski T, and Armstrong JM (1988). Studies on the mode of action for thyroid gland tumor promotion in rats by phenobarbital. Toxicol. Appl. Pharmacol. 94: 254-265.
20. Michalovitz D, Halevy O, and Oren M (1990). Conditional inhibition of transformation of cell proliferation by a temperature-sensitive mutant of p53. Cell 62: 671-680.
21. Myohanen SK, Baylin SB, and Herman JG (1998). Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res. 58: 591-593.
22. Olsen JH, Boice JD Jr, Jenson JPA, and Fraumeni JF Jr (1989). Cancer among epileptic patients exposed to anticonvulsant drugs. J. Natl. Cancer Inst. 81: 803-808.
23. Peraino C, Fry RJ, and Staffeldt E (1971). Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in rats by 2-acetylaminofluorene. Cancer Res. 31: 1506-1512.
24. Peraino C, Fry RJ, and Staffeldt E (1973). Brief communication: Enhancement of spontaneous hepatic tumorigenesis in C3H mice by dietary phenobarbital. J. Natl. Cancer Inst. 51: 1349-1350.
25. Robinson D (1998). The International Life Sciences Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol. Pathol. 26: 474-475 (this issue).
26. Rumsby PC, Davies MJ, and Evans JG (1994). Screening for p53 mutations in C3H/He mouse liver tumors derived spontaneously or induced with diethylnitrosamine or phenobarbitone. Mol. Carcinog. 9: 71-75.
27. Sagartz JE, Bodley WL, Gamblin RM, Couto CG, Tierney LA, and Capen CC (1996). p53 tumor suppressor protein overexpression in osteogenic tumors of dogs. Vet. Pathol. 33: 213-221.
28. Santhanam U, Ray A, and Sehgal PB (1991). Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product Proc. Natl. Acad. Sci. USA 88: 7605-7609.
29. Tennant RW, French JE, and Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect. 103: 942-950.
30. Tennant RW, Spalding J, and French JE (1996). Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat. Res. 365: 119-127.
31. Wolff GL, Morrissey RL, and Chen JJ (1986). Susceptible and resistant subgroups in genetically identical populations: Response of mouse liver neoplasia and body weight to phenobarbital. Carcinogenesis 7: 1935-1937.